FindTrial
Sign In

Efficacy and safety analysis of progressive gastric cancer after neoadjuvant chemotherapy + immunotherapy

Efficacy and safety analysis of progressive gastric cancer after neoadjuvant chemotherapy + immunotherapy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500101502
Enrollment
Unknown
Registered
2025-04-25
Start date
2024-05-01
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

Observation group:None

Sponsors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Gastric cancer confirmed by pathologic examination; 2.Clinical assessment of progressive gastric cancer before neoadjuvant therapy; 3.Completion of at least 2 cycles of neoadjuvant therapy with chemotherapy or chemotherapy + immunotherapy before surgery; 4.Surgical resection with complete pathologic information.

Exclusion criteria

Exclusion criteria: 1.Combination of other malignant tumors; 2.Occurrence of peritoneal metastasis, liver metastasis, and other distant metastases; 3.Incomplete clinical data.

Design outcomes

Primary

MeasureTime frame
Rate of complete pathological remission;—

Secondary

MeasureTime frame
Incidence of adverse reactions;—

Countries

China

Contacts

Public ContactPeng Zhang

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

zhangpengwh@hust.edu.cn+86 181 8610 0993

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026